Oragenics (NYSEAMERICAN:OGEN) Trading 2.7% Higher – Time to Buy?

Oragenics, Inc. (NYSEAMERICAN:OGEN)’s share price was up 2.7% during mid-day trading on Wednesday . The company traded as high as $1.20 and last traded at $1.16. Approximately 35,262 shares changed hands during mid-day trading, a decline of 87% from the average daily volume of 278,239 shares. The stock had previously closed at $1.13.

Oragenics Stock Performance

The company’s fifty day moving average price is $1.26 and its 200 day moving average price is $2.41. The firm has a market capitalization of $4.79 million, a price-to-earnings ratio of -0.05 and a beta of 0.83.

Oragenics (NYSEAMERICAN:OGEN) last released its quarterly earnings data on Friday, November 7th. The company reported ($1.96) earnings per share for the quarter.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Oragenics stock. Bank of America Corp DE increased its stake in shares of Oragenics, Inc. (NYSEAMERICAN:OGEN) by 7,374.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 15,546 shares of the company’s stock after buying an additional 15,338 shares during the quarter. Bank of America Corp DE owned about 1.89% of Oragenics worth $59,000 at the end of the most recent quarter. 18.71% of the stock is owned by hedge funds and other institutional investors.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.